NCT07620509

Brief Summary

  1. 1.BACKGROUND Population aging is one of the most significant trends of the 21st century.In 2020, 21% of the European population was 65 years of age or older, compared to 16% in 2001.Today, 1 in 9 people is over 60, but it is estimated that by 2050, this will be 1 in 5. Therefore, population aging is a phenomenon that can no longer be ignored. In recent decades, the increase in the number of older people is due to the increase in life expectancy. By 2026, the average life expectancy for men is estimated at 77.65 years, and for women, values are projected to reach 85.5 years.
  2. 2.HYPOTHESES AND OBJECTIVES H0: Knowing the functional reaction times assessed with virtual reality does not help to understand the integrity of the physical, functional, and cognitive abilities of older adults with cognitive impairment, nor can it predict their risk of falling or their level of cognitive impairment.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
20

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started May 2026

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

May 25, 2026

Completed
Same day until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 25, 2026

Completed
1 day until next milestone

First Submitted

Initial submission to the registry

May 26, 2026

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

May 26, 2026

Completed
7 days until next milestone

First Posted

Study publicly available on registry

June 2, 2026

Completed
Last Updated

June 2, 2026

Status Verified

April 1, 2026

Enrollment Period

Same day

First QC Date

May 26, 2026

Last Update Submit

May 26, 2026

Conditions

Outcome Measures

Primary Outcomes (1)

  • Virtual reality reaction time test

    A measurement is taken using the Rezzil reaction time test (measured in milliseconds). This software comprises a collection of training games designed to improve physical and cognitive performance across a wide range of sports within an immersive virtual reality (VR) environment. In microwall mode, a 3x3 grid is presented, and the objective is to respond to a random stimulus projected onto it with a rapid limb movement, making several attempts over 45 seconds. The average reaction time is recorded

    Baseline

Secondary Outcomes (3)

  • Level of cognitive impairment assessed using the Global Deterioration Scale (GDS)

    Baseline

  • Level of cognitive ability assessed using the Cambridge Cognitive Examination-Revised (CAMCOG-R) test

    Baseline

  • Gait functionality measured with the Timed Up and Go Test (TUG test)

    Baseline

Study Arms (1)

Virtual reaction time test Group

EXPERIMENTAL

The intervention will consist of a single session measuring virtual reaction times using Rezill software

Other: Virtual reality reaction time test

Interventions

A measurement is taken using the Rezzil reaction time test (measured in milliseconds). This software comprises a collection of training games designed to improve physical and cognitive performance across a wide range of sports within an immersive virtual reality environment. In microwall mode, a 3x3 grid is presented, and the objective is to respond to a random stimulus projected onto it with a rapid limb movement, making several attempts over 45 seconds.

Virtual reaction time test Group

Eligibility Criteria

Age65 Years+
Sexall
Healthy VolunteersNo
Age GroupsOlder Adult (65+)

You may qualify if:

  • age ≥65 years
  • membership in a patient association with cognitive impairment
  • signed informed consent

You may not qualify if:

  • cardiovascular, pulmonary or musculoskeletal pathology that limits the evaluation
  • inability to understand instructions
  • severe sensory impairment, vertigo, epilepsy or uncontrolled psychosis

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

University of Vigo

Vigo, Pontevedra, 36316, Spain

Location

MeSH Terms

Conditions

Dementia

Condition Hierarchy (Ancestors)

Brain DiseasesCentral Nervous System DiseasesNervous System DiseasesNeurocognitive DisordersMental Disorders

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
SUPPORTIVE CARE
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principal Investigator

Study Record Dates

First Submitted

May 26, 2026

First Posted

June 2, 2026

Study Start

May 25, 2026

Primary Completion

May 25, 2026

Study Completion

May 26, 2026

Last Updated

June 2, 2026

Record last verified: 2026-04

Data Sharing

IPD Sharing
Will not share

Locations